Niagen Bioscience
NAGE
55 hedge funds and large institutions have $17.7M invested in Niagen Bioscience in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 11 closing their positions.
0.82% less ownership
Funds ownership: 15.84% → 15.02% (-0.82%)
2% less capital invested
Capital invested by funds: $18.1M → $17.7M (-$451K)
7% less funds holding
Funds holding: 59 → 55 (-4)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
28% less call options, than puts
Call options by funds: $70K | Put options by funds: $97K
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$55.8K |
| 2 |
Renaissance Technologies
New York
|
+$49.8K |
| 3 |
GI
GAMCO Investors
Greenwich,
Connecticut
|
+$43K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$38.5K |
| 5 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$346K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$167K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$159K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$126K |
| 5 |
D.E. Shaw & Co
New York
|
-$87K |
NAGE Hedge Fund Activity: Q2 2023 in Review
55 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2023, worth a combined $17.7M — down 2.5% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NAGE and 7 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Connor, Clark & Lunn Investment Management (CC&L), opening a new position worth an estimated $55.8K. The largest seller was Millennium Management, cutting an estimated $346K.
- 55 institutional investors held Niagen Bioscience (NAGE) as of Q2 2023, down from 59 in Q1 2023.
- Funds reported $17.7M of Niagen Bioscience stock for Q2 2023, down 2.5% quarter-over-quarter.
- 7 funds opened new Niagen Bioscience positions in Q2 2023 and 11 closed out, a net change of -4 holders.
- The largest Niagen Bioscience buyer in Q2 2023 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $55.8K added.
- The largest Niagen Bioscience seller in Q2 2023 was Millennium Management, an estimated $346K sold.
Based on aggregated 13F filings for Q2 2023.